Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Bills Aim To Reduce Pharma Manufacturing Reliance On China

Training, Technologies To Be Boosted

Executive Summary

A US bipartisan Senate bill and House proposal aim to bring pharma manufacturing from China to closer to home, through partnerships with American universities to train the workforce and develop technologies.

You may also be interested in...



US COVID-19 Relief Law Boosts Pharmaceutical Manufacturing Programs; Is More To Come?

$10bn here and $6bn there on top of what’s left from earlier CARES Act gives government more options on COVID-19 medical countermeasures.

China Takes A Bigger Role In The World Pharma Stage

2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.

China Regulatory Express: Patent Linkage, Data Protection, Bio Five-Year Plan

Important changes are coming to China's Drug Administration Law as the government aims to address through several revisions a number of key issues since the law’s original enactment in 2019.

Topics

UsernamePublicRestriction

Register

PS144754

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel